Foundation for Mitochondrial Medicine

AA

A A
Foundation for Mitochondrial Medicine

Day 6: Stealth BioTherapeutics December 2016 presentation


 

12/6/16 Stealth BioTherapeutics/MitoAction/UMDF/FMM Summary

untitled-design

This summer, Stealth BioTherapeutics (Stealth BT) shared preliminary positive data from the MMPOWER study. The study purpose was to evaluate safety and efficacy of elamipretide (previously known as Bendavia) in adults with primary mitochondrial myopathy and genetically confirmed mitochondrial disease.

Mitochondrial myopathy is primarily characterized by muscle weakness, fatigue, and exercise intolerance. Patients with genetically confirmed mitochondrial disorders may also experience multi-system organ involvement and myriad complications related to the body’s inability to adequately generate energy (ATP) at the cellular level. The MMPOWER trial measured changes in the participant’s ability to complete a Six-Minute Walk Rest, a performance-based measure of functional exercise capacity.

This collaborative presentation is hosted by MitoAction, the United Mitochondrial Disease Foundation, the Foundation for Mitochondrial Medicine, with Stealth BT to learn more about the results from the MMPOWER trial, and information about the planned Phase 3 clinical trial. This special presentation educates and informs patients, parents, caregivers, family members, and others involved in the daily lives of adults and children with mitochondrial disease.

Stealth BT, UMDF, MitoAction and FMM are pleased to share with you the webinar summary.  Please click to view.

Click here for Stealth/MitoAction/UMDF/FMM 12/6/16 Update Summary

makes-2

Stay Connected with FMM

  • This field is for validation purposes and should be left unchanged.
Translate »